Register Now!
This presentation provides an overview of Obsteonecrosis of the Jaw (ONJ) and Medication-Related Osteonecrosis of the Jaw (MRONJ), focusing on understanding its types, definitions, causes, and management strategies. Participants will learn to identify and describe the three primary types of ONJ and the core elements that define MRONJ. Dr. Beals will cover the indications for antiresorptive medications, exploring the mechanisms of action for drugs like Denosumab and Bisphosphonates and detailing both anabolic and anti-catabolic medication categories.
Additionally, the presentation will cover the pathophysiology, stages, and predisposing factors of MRONJ, providing a solid foundation for understanding its progression and impact. It will also address treatment goals, the American Association of oral Maxillofacial Surgeons (AAOMS) guidelines, and local wound care practices that promote healing.
Participants will examine the "4 Ds" of antiresorptive therapy, the delayed dosing protocol, and specialized decision-making tools, such as extraction and MRONJ decision trees for Complex Dental Management and Assessment (CDMA) cases. Through these elements, the presentation aims to equip learners with practical strategies and evidence-based approaches for managing MRONJ in clinical settings.
Instructor: Douglas W. Beals, D.D.S, M.S.
Dr. Beals received his Bachelor of Science degree in 1988, his Doctorate of Dental Surgery degree in 1993 and his Master of Science degree in 1997 from The Ohio State University. He entered private practice in Scottsdale, Arizona in 1997. He is a Board Certified Oral and Maxillofacial Surgeon and a fellow of the American Association of Oral and Maxillofacial Surgeons.
Dr. Beals is currently an Associate Professor Oral Surgery at Midwestern University, College of Dental Medicine - Arizona. Dr. Beals joined the clinical faculty in 2015.
Educational Objectives:
- Identify and describe Osteonecrosis of the Jaw (ONJ) and Medication-Related ONJ (MRONJ).
- Explain the mechanisms of action and therapeutic uses of medication involved in managing Osteonecrosis of the Jaw, and ONJ, including antieresorptive and anabolic agents.
- Discuss antiresorptive therapy and its guidelines.
- Recognize predisposing factors and treatment goals in MRONJ.
- apply decision-making tools for extraction and MRONJ.
CDE Coursework Units: 1.5
Tuition: $59 (Due to the Joint Provider ship of this program with ACDE, UCSF Faculty and Staff discounts are not available.)
Cancellation/Refunds:
Tuition refund, less a $25 cancellation fee, will be issued only for cancellations received in writing at least 3 business days prior to the start date of the course. No refunds will be issued for late cancellations or no-shows. We reserve the right to cancel any course due to circumstances beyond our control; under those circumstances we will refund all course fee payments. Please be aware that UCSF School of Dentistry CDE is not responsible for reimbursement of nonrefundable airline tickets or any other travel expenses in the event that a course is canceled.
ACDE Joint Providership
This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint efforts with the Association for Dental Education (ACDE).